GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro) facilitate significant weight loss of 15-20 per cent in clinical trials. However, a recent meta-analysis published in the British Medical Journal indicates these drugs may not meaningfully improve patient quality of life and raises questions regarding long-term cardiovascular benefits and the high likelihood of weight regain … Read more
Eli Lilly reported second-quarter revenue of $23 billion, a 48% increase year over year, driven by soaring demand for its GLP-1 medications Mounjaro and Zepbound, according to the company’s earnings report. The pharmaceutical giant subsequently raised its annual revenue guidance to a range between $85 billion and $87 billion, pushing its stock price up nearly … Read more
The Weight-Loss Revolution: How Biotech is Rewriting Global Health Driving through the quiet, rolling farmland of Dunderrow, Ireland, you would never guess you are approaching the epicenter of a global medical revolution. Yet, hidden within Eli Lilly’s sprawling 50-hectare campus, the future of human health is being manufactured at an unprecedented scale. View this post … Read more
The Great Weight Loss Democratization: Beyond the Luxury Jab For years, GLP-1 agonists like Ozempic and Wegovy were viewed as “miracle drugs” reserved for the wealthy or those with severe medical necessity. However, a seismic shift is occurring in the global pharmaceutical landscape, with India leading the charge. The expiration of key patents on semaglutide … Read more
The Evolution of GLP-1 Therapy: Beyond Blood Sugar Control The landscape of Type 2 diabetes management is shifting. While medications like Ozempic and Mounjaro were originally developed to control blood sugar, their impact is extending far beyond the glycemic index. We are seeing a transition where these tools are no longer viewed as standalone cures, … Read more
The GLP-1 Gold Rush: Is India Ready for the Future of Weight Loss? For decades, weight loss in India was a battle of willpower, restrictive diets, and grueling gym hours. But a seismic shift is happening. The conversation has moved from “which diet works” to “which injectable is better.” Drugs like Mounjaro and Ozempic, originally … Read more
The Mounjaro Rollercoaster: Weight Loss Successes and the Search for Side-Effect-Free Solutions Antony Hawman’s story is becoming increasingly common. The 48-year-old Londoner lost six stone using Mounjaro, a GLP-1 receptor drug, but his journey wasn’t without significant hurdles. Severe vomiting, diarrhoea, and dehydration plagued him initially, highlighting a crucial reality: while these medications can be … Read more
The Future of Weight Loss: Beyond the Injection Weight loss injections like Mounjaro and Ozempic have rapidly develop into mainstream, fueled by celebrity endorsements and compelling clinical trial results. But as more people experience the benefits – and the challenges – of these GLP-1 based medications, a crucial question arises: what’s next? The future of … Read more
The Rise of Weight-Loss Drugs: Beyond Aesthetics and Into Personalized Medicine Comedian Aishwarya Mohanraj’s recent public sharing of her 22kg weight loss journey using Mounjaro has ignited a broader conversation about the increasing accessibility and acceptance of pharmaceutical interventions for weight management. While weight-loss drugs aren’t new, the current landscape, marked by medications like Mounjaro … Read more
The Unexpected Side Effect of Weight Loss Drugs: A Return to ‘Pirate Disease’ The soaring popularity of GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro has brought a surprising health concern to light: scurvy, a disease historically associated with pirates and severe vitamin C deficiency. Although these medications offer significant benefits for weight management, a … Read more